Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ADVINVEST IN ACQUISITION AND ACQUISITION FINANCING OF A MAJORITY STAKE IN ADVANIA
Mandate

VINGE ADVISES ADVINVEST IN ACQUISITION AND ACQUISITION FINANCING OF A MAJORITY STAKE IN ADVANIA

September 19, 2014

Vinge assists a group of Swedish investors through AdvInvest AB in connection with its acquisition financing and acquisition through AdvInvest of a majority stake in Advania. Advania is a Nordic IT company with approx. 1,100 employees in 17 offices in Iceland, Sweden and Norway. Beringer Finance assisted AdvInvest as corporate finance advisor.

Vinge’s team consisted of among others responsible partner Henrik Wenckert (M&A) and project manager Peter Sundgren (M&A) as well as associates Louise Brorsson Salomon (Banking & Finance), Oscar Rydén (Banking & Finance), Albert Wållgren (Banking & Finance), Filip Brosset (M&A), Johan Wahlbom (EU & Competition), Evelina Tejle (Employment & Benefits), Nicklas Thorgerzon (Technology & Outsourcing), Rebecka Weitzberg (Intellectual Property) and Daniel Unger (Real Estate).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026